Moderna (MRNA.US) stock rose over 10% during today's session after the vaccine maker reported solid quarterly results.
- The biotech company earned an adjusted $11.29 per share on $7.2 billion of revenue, easily beating market expectations of $9.90 in earnings per share on $6.78 billion of revenue.
- The company’s CEO told CNBC that he thought people would need another Covid booster shot in the fall.
- Modeerna expects at least $19 billion ofcoronavirus vaccine - Spikevax sales in 2022, with additional signed options of approximately $3 billion.
- Company unveiled a new $3 billion share repurchase plan.
Moderna (MRNA.US) stock fell sharply in recent months, however it seems that buyers managed to halt declines around $149.60 level which coincides with 78.6% Fibonacci retracement of the upward wave launched at the beginning of 2020 and 50 SMA (green line). As long as the price sits above this level, upward move may be resumed. On the other hand, if sellers manage to regain control, then another downward impulse towards support at $56.55 may be launched. Source: xStation5
Meta Announces Its Own AI Chips. Is the Era of Full Dependence on NVIDIA Slowly Coming to an End?
Vodafone shares surge 13% after Xavier Niel's £4.4 billion investment. What's next for the stock?
🚩 Apollo Global warns on AI: Has the market become too optimistic?
Stock of the Week: Seagate Technology. How an old technology found a new role in the era of artificial intelligence